血清miR-345、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性分析

doi:10.3969/j.issn.1671-7171.2024.05.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1232 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨血清微小RNA-345(miR-345)、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性。【方法】100例均接受同一化疗方案治疗的晚期胃癌患者,依据疗效分为有效组(n=69)及无效组(n=31),比较两组临床病理特征及血清相关指标,绘制受试者工作特征(ROC)曲线分析血清miR-345、miR-138及miR-22预测晚期胃癌化疗效果的价值,采用多因素Logistic回归分析影响患者化疗效果的因素。【结果】Ⅲ期患者的血清miR-345相对表达量低于Ⅳ期患者,miR-138及miR-22相对表达量高于Ⅳ期患者(P<0.05);有效组miR-345低于无效组,miR-138、miR-22高于无效组(P<0.05)。经ROC曲线分析证实,血清miR-345、miR-138及miR-22能用于预测晚期胃癌的化疗效果,其敏感度与特异性分别为0.855、0.935、0.971、0.839和0.884、0.903(均P<0.05)。多因素Logistic回归分析显示,病理分期为Ⅳ期、miR-345≥14.5、miR-138≤2及miR-22≤3.12为晚期胃癌患者化疗效果不佳的危险因素(P<0.05)。【结论】血清miR-345≥14.5、miR-138≤2、miR-22≤3.12均为导致化疗效果不佳的危险因素,其可作为评估患者化疗效果的生物学标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周士霞
	王海莉

关键词 ：胃肿瘤, 微RNAs, 抗肿瘤药, 数据相关性

Abstract：【Objective】To explore serum microRNA-345 (miR-345) The correlation between miR-138 and miR-22 and chemotherapy sensitivity in advanced gastric cancer patients. 【Methods】A total of 100 patients with advanced gastric cancer who received the same chemotherapy regimen were divided into an effective group of 69 cases and an ineffective group of 31 cases based on their efficacy. The clinical and pathological characteristics and serum related indicators of the two groups were compared, and the receiver operating characteristic (ROC) curve was plotted. The serum miR-345 was analyzed. The value of miR-138 and miR-22 in predicting the chemotherapy efficacy of advanced gastric cancer was analyzed using multivariate logistic regression to identify the factors that affect the chemotherapy efficacy of patients.【Results】The relative expression level of serum miR-345 in stage Ⅲ patients was low than those of stage Ⅳ patients (P<0.05). The relative expression levels of miR-138 and miR-22 were higher than those of stage Ⅳ patients (P<0.05); miR-345 in the effective group was lower than that in the ineffective group, miR-138 and miR-22 were higher than those in the ineffective group (P<0.05). Confirmed by ROC analysis, serum miR-345, miR-138 and miR-22 can be used to predict the chemotherapy efficacy of advanced gastric cancer, with sensitivity and specificity of 0.855, 0.935, 0.971, 0.839, and 0.884, 0.903, respectively (all P<0.05). Multivariate logistic regression analysis showed that the pathological stage Ⅳ, miR-345 ≥ 14.5, miR-138 ≤ 2, and miR-22 ≤ 3.12 were risk factors for poor chemotherapy efficacy in advanced gastric cancer patients (P<0.05).【Conclusion】Serum miR-345≥14.5, miR-138 ≤ 2 and miR-22 ≤ 3.12 are both risk factors for poor chemotherapy efficacy, and can be used as biological markers to evaluate the chemotherapy efficacy of patients.

Key words： Stomach Neoplasms MicroRNAs Antineoplastic Agents Correlation of Data

收稿日期: 2023-12-15

中图分类号:

R735.2

引用本文:

周士霞, 王海莉. 血清miR-345、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性分析[J]. 医学临床研究, 2024, 41(5): 711-714.
ZHOU Shixia, WANG Haili. Correlation Analysis of Serum miR-345, miR-138 and miR-22 with Chemotherapy Sensitivity in Advanced Gastric Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 711-714.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.05.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I5/711

[1] 吴秀贞, 刘宗超, 覃向向,等.基于胃癌高发区人群筛查队列的不同胃黏膜病变进展为胃癌风险的前瞻性研究[J].中华流行病学杂志,2022,43(12):1972-1978.
[2] 李刚刚, 孙继锋, 张成武, 等. 早期胃癌淋巴结转移危险因素及预后分析[J].中华普通外科杂志,2021,36(10):734-738.
[3] YAMADA T,YOSHIKAWA T,MIZUSAWA J,et al. Risk factors for the continuation of S-1 adjuvant chemotherapy for gastric cancer analyzed from the JCOG1104 phase Ⅲ trial[J].J Clin Oncol,2021, 39(3):196.
[4] 唐德平, 邢梦洁, 宋文涛,等. microRNA治疗在癌症及其他疾病中的研究进展[J].中国生物工程杂志, 2021,41(11):64-73.
[5] ZHANG M Y,LIN J,KUI Y C,et al. MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1[J].Eur Rev Med Pharmacol Sci,2019,23(6):2436-2443.
[6] 吴闽, 侯慧珍, 司廷林. 过表达miR-138抑制TCF-4对甲状腺癌细胞CAL-62增殖、凋亡和运动的调节作用[J].中国临床解剖学杂志, 2019,37(4):425-430.
[7] YUAN S K, ZHANG P T, WEN L Q, et al. miR-22 promotes stem cell traits via activating Wnt/beta-catenin signaling in cutaneous squamous cell carcinoma[J].Oncogene,2021,40(39):5799-5813.
[8] 邱海波, 周志伟. NCCN胃癌临床实践指南2017年第五版更新要点解读[J].中华胃肠外科杂志, 2018,21(2):160-164.
[9] 李欣, 赵久达, 林明哲,等. 老年胃癌患者循环肿瘤细胞与临床病理特征及化疗疗效的关系[J].中国老年学杂志, 2022, 42(3):553-557.
[10] KUMAR S,SESHADRI R A, TRIVADI S G,et al. Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis[J].Asia-Pac J Clin Oncol,2020,16(5):252-256.
[11] HIRAKU Y,WATANABE J,KANEKO A,et al. MicroRNA expression in lung tissues of asbestos-exposed mice: Upregulation of miR-21 and downregulation of tumor suppressor genes Pdcd4 and Reck[J].J Occup Health,2021,63(1):12282.
[12] 孙婧悦, 王啸, 王振欣,等. 血清外泌体miRNAs在晚期胃癌患者化疗疗效预测中的价值[J].中国肿瘤临床, 2022,49(4):174-178.
[13] SONG J,LIU Y J, WANG T Y, et al. MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer[J].Biomed Pharmacother,2020,128(7):110246.
[14] ISHIKAWA M,HAYASHI H,SAKAMOTO N,et al. Cancer gene profiling explores the possible precision medicine for diffuse-type gastric adenocarcinoma[J].Med Oncol,2020, 37(1):10.
[15] SOUDEN G F,VAFAEE R,SHOOREI H,et al. MicroRNAs in gastric cancer: Biomarkers and therapeutic targets[J].Gene,2020, 757(10):144937.
[16] YIN C L, ZHENG X X, XIANG H P, et al. Differential expression profile analysis of cisplatin-regulated miRNAs in a human gastric cancer cell line[J].Mol Med Rep,2019,20(2):1966-1976.